金信諾(300252.SZ):擬參設吾同智芯 其投資於江蘇展芯半導體技術
格隆匯7月11日丨金信諾(300252.SZ)公佈,公司與上海吾同投資管理有限公司(簡稱“吾同投資”或“普通合夥人”)以及其他12名合夥企業有限合夥人,簽署了《青島吾同智芯股權投資合夥企業(有限合夥)有限合夥協議》,共同投資青島吾同智芯股權投資合夥企業(有限合夥)(簡稱“吾同智芯”或“合夥企業”“投資基金”)。吾同智芯規模5560萬元,公司以自有資金認繳出資500萬元人民幣,出資比例8.9928%,為合夥企業之有限合夥人之一。基金投資方向僅限於以增資或股權轉讓的方式投資於江蘇展芯半導體技術有限公司,不得進行其他投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.